; and (4) an accounting of Federal funding used to implement such strategies. (b) Report Not later than 18 months after the date of enactment of this Act, the Comptroller General of the United States shall submit a report on the study under subsection (a) to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives. Such report shall include recommendations based on the findings of the study conducted under subsection (a) regarding the impact of such strategies during the COVID–19 public health emergency, including recommendations on how to improve future responses. 212. Emerging pathogens preparedness program (a) In general Section 565 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–4 ) is amended by adding at the end the following: (j) Emerging pathogens preparedness program (1) In general The Secretary shall establish a program to facilitate the development, review, licensure, approval, and clearance of countermeasures, and products that could potentially be countermeasures, under the jurisdiction of the Center for Biologics Evaluation and Research. (2) Activities The activities of the program established under paragraph (1) may include, either directly or by grant, contract, or cooperative agreement, the following: (A) Any activities described in subsection (b). (B) Activities to advance scientific research related to the development of tools, standards, and approaches to assess the safety, efficacy, quality, and performance of countermeasures. (C) Activities to maintain or enhance surveillance programs that monitor countermeasures. (D) Activities to help ensure blood safety and availability. (E) Prioritizing the research and development of platform vaccine technologies to support an emergency use authorization request under section 564 or an application under section 351(a) of the Public Health Service Act. (F) Such other activities as the Secretary determines necessary or appropriate. (3) Rule of construction